2009-05-11 21:38:04 -

NeuroMetrix, Inc. (Nasdaq: NURO), a health care company transforming patient care through neurotechnology, today announced that Dr. Shai N.

Gozani, Chief Executive Officer and President, will be presenting at the Canaccord Adams Diabetes & Obesity Conference on Tuesday, May 12, 2009 at the InterContinental Barclay Hotel in New York.

NeuroMetrix’s presentation is scheduled for Tuesday, May 12, 2009 at 2:00 p.m.

The presentation will be available on webcast at www.neurometrix.com : within our “Investor Relations” tab.

About NeuroMetrix


NeuroMetrix is a science-based healthcare company transforming patient care through neurotechnology. To date, our focus has been primarily on the assessment of neuropathies. Neuropathies affect the peripheral nerves and parts of the spine and are frequently caused by or associated with carpal tunnel syndrome, diabetes, sciatica, and other clinical disorders. We market systems for the performance of nerve conduction studies and needle electromyography procedures. Our product pipeline includes a system designed to deliver pharmacologic agents such as anesthetics and corticosteroids in close proximity to nerves for regional anesthesia, pain control and the treatment of focal neuropathies. We are also developing neurostimulation-based devices that promote nerve fiber regeneration in acute peripheral nerve and spinal cord injuries. For more information, visit www.neurometrix.com : .



NeuroMetrix, Inc.Joseph A. Calo, 781-314-2775Acting Chief
Financial Officer neurometrix.ir@neurometrix.com : mailto:neurometrix.ir@neurometrix.com